RxDoctor Payments Data

Adair Laboy, MD

Nephrology · San Juan, PRNPI 1952335481

Payments from drug & device makers

$2,489in general payments, 2019–2025

Across 64 payments — averaging $38.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$814
  • E.r. Squibb & Sons, L.L.C.$461
  • Bayer$269
  • Johnson & Johnson$211
  • Merck$170
  • Mallinckrodt Hospital Products Inc.$117
  • plus $447 from 8 others

What the payments were for

  • Food & beverage$2,38996%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca36$814
E.r. Squibb & Sons, L.L.C.5$461
Bayer4$269
Johnson & Johnson6$211
Merck2$170
Mallinckrodt Hospital Products Inc.2$117
Boston Scientific1$102
Vifor Pharma, Inc.1$100
AbbVie1$100
Amgen1$49
Bayer Puerto Rico Inc.2$38
ANI Pharmaceuticals, Inc.1$25
PBG Puerto Rico LLC1$20
Boehringer Ingelheim1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,489 in reported general payments places this provider in the 55th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$23,505
Medicare patients
69
Services billed
247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate59$36,631
JardianceEmpagliflozin24$20,789
FarxigaDapagliflozin Propanediol27$18,163
Sevelamer Carbonate113$16,956
RetacritEpoetin Alfa-Epbx25$11,574
Calcium Acetate99$10,246
Lanthanum Carbonate19$7,566
SynthroidLevothyroxine Sodium35$2,167
Hydralazine Hcl123$1,617
Calcitriol58$1,510
Doxazosin Mesylate50$1,231
Irbesartan55$956
Gabapentin68$820
Pentoxifylline18$735
Metoprolol Succinate55$674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$814$54,79486 claims
Boehringer IngelheimJardiance$14$20,78924 claims
AbbVieSynthroid$100$2,16735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →